Member Info for daveycaferacer

Great news indeed! and hopefully this is still to come before the end of the year

1. Initiation of a global study of savolitinib/ Tagrisso® combo in 2L/3L NSCLC post Tagrisso® failure; AZ presents data on c-Met resistance; regulatory dialogue;

2. Molecular epidemiology study (n>200) in PRCC [3] – possibly BTD enabling

Thankyou Azurite, they have been a big fan for many years now

Great volume into the close (market closes at 1pm today), 420,000 traded

Close price $33.91 up 5.15% = circa £53

Chi-Med subsidiary Hutchison MediPharma received "R&D Achievement of the Year" Award from BayHelix at BioCentury China Healthcare Summit in Shanghai, for China approval of fruquintinib for colorectal cancer - 1st China-discovered & developed cancer drug unconditionally approved.

It appears what is really a minor setback is now being treated as it should be by the market. In other words it will have a small impact on the value of the IP in the Pipeline, and a small impact on future revs and earnings, but there are much bigger prizes to come......

Ok interesting miti, thanks, I didn't realise this index could include foreign listed shares - thanks for the intel, as you say, this could make a difference as Index funds start to buy!

I think it is Ceridian HCM Holding that is being added to the index

This gave me a welcome break from reading the Brexit Withdrawal Agreement!

miti, interesting......

CK Life Sciences Int (Holdings) have a HK listing that is separate from CK Hutchison Holdings - stock code: 0775 but not HCM

Also, Hutchison Healthcare Holdings Limited is a subsidiary of HWL but I do not think it has a separate listing

Interesting to consider that when Frquintinib NDA was approved the share price barely moved and yet poor trial results in another indication causes a 20% drop.

We have these to look forward to before the end of the year.......hopefully positive, I am particularly excited about the possibility of BTD for PRCC

1. Initiate global study of savolitinib/ Tagrisso® combo in 2L/3L NSCLC post Tagrisso® failure; AZ presents data on c-Met resistance; regulatory dialogue;

2. Molecular epidemiology study (n>200) in PRCC [3] – possibly BTD enabling.

My holding is into 5 figures in terms of numbers of shares, although a little behind Miti but I will catch up at some point ;o-)

I have bought more this morning, never selling, only buying ;o-) more pipeline updates coming!

A disappointing update today on the FALUCA trial, however there's plenty more updates to come from a pipeline much larger Companies would love to have in their asset portfolio

Less volume on NASDAQ today than yesterday but still high compared to the average and another 4 hrs to go yet

1.71 million volume at the closing bell yesterday

Still trading at less than we were in January 2018 so no alarm bells from my perspective

At 13:20 on NASDAQ the volume just exceeded 1 million, which I have not seen before since the last fundraising

Yes! top-line data for Phase III FALUCA study in 3L NSCLC imminent quickly followed by the second NDA :o-)

I need to buy some more...

I just purchased a small quantity @ £49.50, I will be making a much larger purchase within the next 14 days ;o-)

We are due 3 major pipeline updates before the end of the year, although I'm surprised we had little movement at the time of Frquintinib/Elunate approval.

Edison value is £74 and it usually follows within 6 months of their updates, historically ....

Yes! I will be doing it today ;o-)

I will also be adding substantially within the next few days ;o-)